Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 621

1.

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Fernandez HH, Chen JJ.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):174S-185S. Review.

PMID:
18041937
2.
3.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
4.

Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

Henchcliffe C, Schumacher HC, Burgut FT.

Expert Rev Neurother. 2005 Nov;5(6):811-21. Review.

PMID:
16274338
5.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
6.
7.
8.
9.

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

Elmer LW, Bertoni JM.

Expert Opin Pharmacother. 2008 Nov;9(16):2759-72. doi: 10.1517/14656566.9.16.2759 . Review.

PMID:
18937611
10.
11.

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group..

Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30.

PMID:
11575866
12.

Rasagiline: a review of its use in the management of Parkinson's disease.

Oldfield V, Keating GM, Perry CM.

Drugs. 2007;67(12):1725-47. Review.

PMID:
17683172
13.

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Chen JJ, Ly AV.

Am J Health Syst Pharm. 2006 May 15;63(10):915-28. Review.

PMID:
16675649
14.

Rasagiline.

Siddiqui MA, Plosker GL.

Drugs Aging. 2005;22(1):83-91; discussion 93-4. Review.

PMID:
15663351
15.

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.

Caslake R, Macleod A, Ives N, Stowe R, Counsell C.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006661. doi: 10.1002/14651858.CD006661.pub2. Review.

PMID:
19821381
16.

The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.

Sieradzan K, Channon S, Ramponi C, Stern GM, Lees AJ, Youdim MB.

J Clin Psychopharmacol. 1995 Aug;15(4 Suppl 2):51S-59S.

PMID:
7593732
17.

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Review.

PMID:
20600573
18.

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Jost WH, Klasser M, Reichmann H.

Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. German.

PMID:
18833504
19.

[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

Kassubek J, Büttner T, Reichmann H, Riederer P, Schulz JB, Wüllner U, Csoti I.

Fortschr Neurol Psychiatr. 2010 Mar;78 Suppl 1:S34-6. doi: 10.1055/s-0029-1245166. Review. German.

PMID:
20195940
20.

Monoamine oxidase B inhibitors for early Parkinson's disease.

Macleod AD, Counsell CE, Ives N, Stowe R.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. Review.

PMID:
16034956

Supplemental Content

Support Center